Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Hospital volume of percutaneous radiofrequency ablation is closely associated with treatment outcomes for patients with hepatocellular carcinoma.

Lu LC, Shao YY, Kuo RN, Lin ZZ, Yeh YC, Shau WY, Hsu CH, Cheng AL, Lai MS.

Cancer. 2013 Mar 15;119(6):1210-6. doi: 10.1002/cncr.27800. Epub 2012 Dec 4.

2.

Younger hepatocellular carcinoma patients have better prognosis after percutaneous radiofrequency ablation therapy.

Kao WY, Chiou YY, Hung HH, Su CW, Chou YH, Huo TI, Huang YH, Wu WC, Lin HC, Lee SD, Wu JC.

J Clin Gastroenterol. 2012 Jan;46(1):62-70. doi: 10.1097/MCG.0b013e31822b36cc.

PMID:
21934530
3.

Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma.

Wang JH, Wang CC, Hung CH, Chen CL, Lu SN.

J Hepatol. 2012 Feb;56(2):412-8. doi: 10.1016/j.jhep.2011.05.020. Epub 2011 Jul 12.

PMID:
21756858
4.

Radiofrequency ablation of hepatocellular carcinoma: long-term outcome and prognostic factors.

Yan K, Chen MH, Yang W, Wang YB, Gao W, Hao CY, Xing BC, Huang XF.

Eur J Radiol. 2008 Aug;67(2):336-47. Epub 2007 Aug 31.

PMID:
17765421
5.

Percutaneous radiofrequency ablation as first-line treatment for small hepatocellular carcinoma: results and prognostic factors on long-term follow up.

Waki K, Aikata H, Katamura Y, Kawaoka T, Takaki S, Hiramatsu A, Takahashi S, Toyota N, Ito K, Chayama K.

J Gastroenterol Hepatol. 2010 Mar;25(3):597-604. doi: 10.1111/j.1440-1746.2009.06125.x. Epub 2010 Jan 14.

PMID:
20074153
6.

High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma.

Kobayashi M, Ikeda K, Kawamura Y, Yatsuji H, Hosaka T, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Saitoh S, Arase Y, Kumada H.

Cancer. 2009 Feb 1;115(3):571-80. doi: 10.1002/cncr.24031.

7.

Percutaneous radiofrequency ablation therapy for recurrent hepatocellular carcinoma.

Nishikawa H, Osaki Y, Iguchi E, Takeda H, Ohara Y, Sakamoto A, Hatamaru K, Saito S, Nasu A, Kita R, Kimura T.

Anticancer Res. 2012 Nov;32(11):5059-65.

PMID:
23155279
8.

Surgical resection versus radiofrequency ablation for small hepatocellular carcinomas within the Milan criteria.

Ueno S, Sakoda M, Kubo F, Hiwatashi K, Tateno T, Baba Y, Hasegawa S, Tsubouchi H; Kagoshima Liver Cancer Study Group.

J Hepatobiliary Pancreat Surg. 2009;16(3):359-66. doi: 10.1007/s00534-009-0069-7. Epub 2009 Mar 20.

PMID:
19300896
9.

Radiofrequency ablation as first-line treatment for small solitary hepatocellular carcinoma: long-term results.

Peng ZW, Zhang YJ, Chen MS, Lin XJ, Liang HH, Shi M.

Eur J Surg Oncol. 2010 Nov;36(11):1054-60. doi: 10.1016/j.ejso.2010.08.133. Epub 2010 Sep 16.

PMID:
20846819
10.

[Quality of life of primary hepatocellular carcinoma patients after radiofrequency ablation].

Wang YB, Chen MH, Yan K, Yang W, Dai Y, Yin SS.

Ai Zheng. 2005 Jul;24(7):827-33. Chinese.

PMID:
16004809
11.

Impact of radiofrequency ablation on the management of patients with hepatocellular carcinoma in a specialized centre.

Lam CM, Ng KK, Poon RT, Ai V, Yuen J, Fan ST.

Br J Surg. 2004 Mar;91(3):334-8.

PMID:
14991635
12.

[Efficacy of radiofrequency ablation to treat advanced hepatocellular carcinoma].

Wu J, Chen MH, Yang W, Wu W, Yan K.

Zhonghua Gan Zang Bing Za Zhi. 2012 Apr;20(4):256-60. doi: 10.3760/cma.j.issn.1007-3418.2012.04.006. Chinese.

PMID:
22964144
13.

Outcomes of nontransplant potentially curative therapy for early-stage hepatocellular carcinoma in Child-Pugh stage A cirrhosis is comparable with liver transplantation.

Takahashi S, Kudo M, Chung H, Inoue T, Nagashima M, Kitai S, Tatsumi C, Minami Y, Ueshima K, Fukunaga T, Haji S.

Dig Dis. 2007;25(4):303-9.

PMID:
17960064
14.
15.

Percutaneous thermal ablation of medium and large hepatocellular carcinoma: long-term outcome and prognostic factors.

Yin XY, Xie XY, Lu MD, Xu HX, Xu ZF, Kuang M, Liu GJ, Liang JY, Lau WY.

Cancer. 2009 May 1;115(9):1914-23. doi: 10.1002/cncr.24196.

16.

Initial treatment response is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy.

Takahashi S, Kudo M, Chung H, Inoue T, Ishikawa E, Kitai S, Tatsumi C, Ueda T, Minami Y, Ueshima K, Haji S.

Oncology. 2007;72 Suppl 1:98-103. Epub 2007 Dec 13.

PMID:
18087189
17.

[Comparison of radiofrequency ablation and transarterial chemoembolization for the treatment of a single hepatocellular carcinoma smaller than 4 cm].

Yang MJ, An SY, Moon EJ, Lee MS, Hwang JA, Cheong JY, Won JH, Kim JK, Wang HJ, Cho SW.

Korean J Hepatol. 2009 Dec;15(4):474-85. doi: 10.3350/kjhep.2009.15.4.474. Korean.

PMID:
20037266
18.

Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases.

Tateishi R, Shiina S, Teratani T, Obi S, Sato S, Koike Y, Fujishima T, Yoshida H, Kawabe T, Omata M.

Cancer. 2005 Mar 15;103(6):1201-9.

19.

Surgical radiofrequency ablation for treatment of hepatocellular carcinoma: an endoscopic or open approach.

Tanaka S, Shimada M, Shirabe K, Taketomi A, Maehara S, Tsujita E, Ito S, Kitagawa D, Maehara Y.

Hepatogastroenterology. 2009 Jul-Aug;56(93):1169-73.

PMID:
19760963
20.

Comparison of radiofrequency ablation and transarterial chemoembolization for hepatocellular carcinoma within the Milan criteria: a propensity score analysis.

Hsu CY, Huang YH, Chiou YY, Su CW, Lin HC, Lee RC, Chiang JH, Huo TI, Lee FY, Lee SD.

Liver Transpl. 2011 May;17(5):556-66. doi: 10.1002/lt.22273.

Supplemental Content

Support Center